Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Free Cash Flow for 7 consecutive years, with -$66.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 6.59% to -$66.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$234.3 million through Dec 2025, down 13.02% year-over-year, with the annual reading at -$234.3 million for FY2025, 13.02% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$66.9 million at Kymera Therapeutics, down from -$27.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$3.6 million in Q4 2023, with the low at -$79.6 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$43.3 million, with a median of -$40.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow soared 91.03% in 2023, then tumbled 1651.96% in 2024.
  • Over 5 years, Free Cash Flow stood at -$38.9 million in 2021, then fell by 2.72% to -$39.9 million in 2022, then skyrocketed by 91.03% to -$3.6 million in 2023, then crashed by 1651.96% to -$62.7 million in 2024, then fell by 6.59% to -$66.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$66.9 million, -$27.3 million, and -$60.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.